The pharmacodynamic parameters that have been evaluated
for albiglutide include its effects on glucose, insulin,
C-peptide, glucagon, fasting plasma glucose, postprandial
plasma glucose, free fatty acids, and fructosamine. Healthy
subjects who received increasing doses of albiglutide showed
a trend of dose-dependent reduction in glucose and fructosamine
levels. In these healthy subjects, there were no dosedependent
effects seen for glucagon, insulin, or C-peptide
concentrations.12